Journals / Anadolu Kardiyoloji Dergisi / 2012 / Cilt: 12 - Sayı: 2

Koroner arter hastalığında atorvastatinin günlük kullanıma karşın-gün aşırı kullanımı: Randomize bir çalışma

Alternate-day versus daily atorvastatin in coronary artery disease: A randomized study

Pages
90–96
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Similarly, the mean percent increase of LDL-C from baseline to final assessment was signifi- cantly lower in Group A as compared with Group B (1.5±0.2 versus 32.8±6.2%, respectively, p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: We sought to compare the effect of alternate-day versus daily atorvastatin 10 mg, on serum low-density lipoprotein cholesterol (LDL-C) and high-sensitivity C-reactive protein (hs-CRP) in patients with coronary artery disease (CAD) and controlled serum LDL-C by daily atorvastatin.
📊
Key Findings & Data:Randomization was performed by a computer-generated random- ization list.
💡
Conclusion & Impact:Similarly, the mean percent increase of LDL-C from baseline to final assessment was signifi- cantly lower in Group A as compared with Group B (1.5±0.2 versus 32.8±6.2%, respectively, p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: We sought to compare the effect of alternate-day versus daily atorvastatin 10 mg, on serum low-density lipoprotein cholesterol (LDL-C) and high-sensitivity C-reactive protein (hs-CRP) in patients with coronary artery disease (CAD) and controlled serum LDL-C by daily atorvastatin. Methods: The study was prospective, randomized, single-blinded, two-armed. Randomization was performed by a computer-generated random- ization list. We randomized 60 patients with CAD and controlled serum LDL-C to receive either atorvastatin in the standard-dose of 10 mg daily (Group A=30 patients), or the same medication every other day (Group B=30 patients). Primary efficacy criterion included changes in serum LDL-C and hs-CRP from the initial to the 6-week follow-up values. Results: The mean age was 54.5±7.7 years, (70% males). LDL-C was significantly lower in Group A as compared with group B at 6-week follow-up (88±21 versus 105±26 mg/dl, respectively, p=0.008). Similarly, the mean percent increase of LDL-C from baseline to final assessment was signifi- cantly lower in Group A as compared with Group B (1.5±0.2 versus 32.8±6.2%, respectively, p

Özet

Amaç: Koroner arter hastalığı (KAH) olan hastalarda, serum düşük dansiteli lipoprotein kolestrol (LDL-K) ve yüksek duyarlılıklı C-reaktif protein (hs-CRP) üzerine günlük atorvastatin 10 mg’a karşılık gün aşırının etkisini karşılaştırmayı amaçladık ve LDL-K’yı günlük atorvastatinle kontrol ettik. Yöntemler: Prospektif, randomize, tek kör ve çift kollu bir çalışmadır. Randomizasyon bir bilgisayar tarafından randomizasyon listesi ile yapıldı. Koroner arter hastalığı olan 60 hastayı randomize ettik, günlük standart doz 10 mg atorvastatin alan (Grup A=30 hasta) ya da aynı tıbbi tedaviyi her gün alanların kontrollü serum LDL-K’ını kontrol ettik (Grup B=30 hasta). Primer etkinlik kriteri, başlangıçtan itibaren 6 haftalık takip değerle- rindeki serum LDL-K ve hs-CRP seviyelerinin değişikliklerini içermektedir. Bulgular: Ortalama yaş 54.5±7.7 yıldır (%70 erkek). Altı haftalık takipte, LDL-K değeri, Grup A Grup B ile karşılaştırıldığında, önemli derece düşük- tü (88±21 karşın 105±26 md/dl, sırasıyla, p=0.008). Benzer şekilde, başlangıçtan son değerlendirmeye ortalama LDL-K artış yüzdesi Grup A’ dakilerle Grup AB’dekilerle karşılaştırıldığında önemli derecede düşüktü (1.5±0.2 karşın %32.8±6.2, sırasıyla, p

🔖

Cite This Article

ZAHRAN, A., NAMMAS, W., RIFAIE, O. (2022). Koroner arter hastalığında atorvastatinin günlük kullanıma karşın-gün aşırı kullanımı: Randomize bir çalışma. Anadolu Kardiyoloji Dergisi, Cilt: 12 - Sayı: 2, 90–96. https://ajindex.com/articles/436334

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Thavendiranathan P Bagai A, Brookhart MA, Choudhry NK. Primary prevention of cardiovascular diseases with statin therapy: a meta- analysis of randomized controlled trials. Arch Intern Med 2006; 166: 2307-13. [CrossRef] 2. Cannon CP Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-504. [CrossRef] 3. Ridker PM, Rifai N, Pfeffer M, Sacks F, Braunwald E. Long term effects of pravastatin on plasma concentration of C-reactive protein. The cholesterol and recurrent events (CARE) investigators. Circulation 1999; 100: 230-5. 4. Albert MA, Danielson E, Rifai N, Ridker PM; PRINCE investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin/ inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286: 64-70. [CrossRef] 5. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Measurement of C-reactive protein for the targeting of statin therapy in primary prevention of acute coronary events. N Engl J Med 2001; 344: 1959-65. [CrossRef] 6. Ozaki K, Kubo T, Imaki R, Shinagawa H, Fukaya H, Ohtaki K, et al. The anti-atherosclerotic effects of lipid lowering with atorvastatin in patients with hypercholesterolemia. J Atheroscler Thromb 2006; 13: 216-9. [CrossRef] 7. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002; 288: 455-61. [CrossRef] 8. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007; 297: 177-86. [CrossRef] 9. Doshi JA, Zhu J, Lee BY, Kimmel SE, Volpp KG. Impact of a prescription copayment increase on lipid-lowering medication adherence in veterans. Circulation 2009; 119: 390-7. [CrossRef] 10. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421. 11. Friedewald WT, Levy RI, Frederickson DS. Estimation of concentration of low-density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem 1972; 18